

**Food and Drug Administration Advisory Committee Member  
Acknowledgment of Financial Interests**

Name of Advisory Committee Temporary Voting Member: **Edward Pritchett, M.D.**

Committee: Psychopharmacologic Drugs Advisory Committee

Meeting Date: June 9-10, 2009

I acknowledge that contingent upon public disclosure of the following financial interest(s) related to the agenda items: The new drug applications (NDAs): 1) NDA 20-639/S-045 and S-046: Seroquel (quetiapine fumarate), AstraZeneca Pharmaceuticals LP, for (a) the acute treatment of schizophrenia in adolescents (13-17 years of age), and (b) the acute treatment of bipolar mania in children (10-12 years of age) and adolescents (13-17 years of age); 2) NDA 20-825/S-032: Geodon (ziprasidone hydrochloride), Pfizer Inc., for the acute treatment of manic or mixed episodes associated with bipolar disorder, with or without psychotic features in children and adolescents ages 10-17 years; and 3) NDA 20-592/S-040 and S-041: Zyprexa (olanzapine), Eli Lilly and Company, for (a) the acute treatment of manic or mixed episodes associated with bipolar I disorder, and (b) the acute treatment of schizophrenia in adolescents. The committee will be asked to vote on whether or not these products have been shown to be effective and acceptably safe for these pediatric indications, I may be considered for participation in the advisory committee meeting described above.

<u>Type of Interest</u>	<u>Nature</u>	<u>Magnitude</u>
<b>I. Personal/Immediate Family</b>		
Stock ownership	Two competing firms	Worth between \$5,001 - 10,000 and \$25,001 – 50,000;
<b>Imputed Interests</b>		
None	None	None

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of this interest, I will not participate in the advisory committee meeting described above.

\_\_\_\_\_/s/\_\_\_\_\_  
Signature

4-29-2009  
Date